Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP1 | P53582 | 6/20 | 0.63 |
| ▸ | ACHE | P22303 | 7/20 | 0.50 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.48 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | HTR7 | P34969 | 1/20 | 0.43 |
| ▸ | HRH1 | P35367 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
| ▸ | HTR2B | P41595 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7305377 | 0.85 | METAP1 (0.59) | METAP1ACHECYP19A1HTR2CSIGMAR1 | |
| SCHEMBL30620900 | 0.84 | HTR2A (0.54) | METAP1ACHEHTR2A | |
| SCHEMBL6273185 | 0.83 | METAP1 (0.59) | METAP1ACHECYP19A1HTR1ADRD2 | |
| SCHEMBL6272087 | 0.81 | METAP1 (0.64) | METAP1ACHECYP19A1 | |
| SCHEMBL6695612 | 0.81 | METAP1 (0.57) | METAP1ACHECYP19A1HTR1ADRD2 | |
| SCHEMBL6272440 | 0.80 | METAP1 (0.65) | METAP1ACHECYP19A1HTR1ADRD2 | |
| SCHEMBL6272068 | 0.80 | HTR2C (0.47) | METAP1ACHECYP19A1HTR1ADRD2 | |
| SCHEMBL7737589 | 0.79 | METAP1 (0.52) | METAP1ACHECYP19A1HTR1ADRD2 | |
| SCHEMBL9938389 | 0.79 | METAP1 (0.55) | METAP1ACHECYP19A1HTR1ADRD2 | |
| SCHEMBL31374607 | 0.79 | METAP1 (0.55) | METAP1ACHECYP19A1HTR1ADRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050277645-A1 | Sleep inducing compounds and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2005-12-15 | — | — | US | disclosed |
| WO-2005097093-A1 | SLEEP INDUCING COMPOUNDS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES, INC. (US) | 2005-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050277645-A1 | Sleep inducing compounds and methods relating thereto | CNR1, CNR2, MTNR1B | METAP1 4516/4885ACHE 652/4885CYP19A1 395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.